Should I buy Gilead Sciences (GILD) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $163 (+10 %), call made on October 8, 2026, maturing on October 8, 2027 (6 d ago).
Firm-by-firm track record on Gilead Sciences
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 89 % | +61.1 % | 9 | $155 +5% |
| JP Morgan | 91 % | +34.8 % | 11 | $170 +15% |
| Wells Fargo | 86 % | +26.0 % | 7 | $165 +12% |
| Morgan Stanley | 69 % | +23.1 % | 13 | $163 +10% |
| Barclays | 50 % | +21.0 % | 10 | $145 -2% |
| Citigroup | 50 % | +10.9 % | 10 | $165 +12% |
| RBC Capital | 60 % | +6.5 % | 10 | $126 -15% |
| Cantor Fitzgerald | 40 % | -3.8 % | 5 | $155 +5% |
✅ Reasons to believe
- 70% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
- Median price target $161, i.e. +9% from the current price ($148).
- The most reliable firm on GILD, JP Morgan (91% hit rate, 11 scored calls), targets $170 (call made on October 7, 2026, maturing on October 7, 2027) (+15%) in its most recent call, and $150 (call made on October 31, 2025, maturing on October 31, 2026) (+1%) in the one coming due soonest.
- Pays a dividend (2.6% yield), raised for 10 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 10 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on GILD
Median target $161 (+9%) · 10 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Gilead Sciences now?
We won't decide for you. The facts: 70% of analysts rate it a buy, median target $161 (+9%), and JP Morgan (most reliable on GILD, 91%) targets $170. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Gilead Sciences?
Not according to analysts: the median target ($161) is still +9% above the current price ($148) (most reliable on GILD: JP Morgan, 91%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Gilead Sciences still worth investing in?
It depends on the gap between the price ($148) and its estimated value: analysts target $161 on median (+9%), with 70% buys (most reliable on GILD: JP Morgan, 91%). Cross-check with their real reliability on GILD and the cautions above. Information, not advice.
What's the main risk in buying GILD?
The consensus is not unanimous: of 10 ratings, 3 are neutral.
→ Go deeper: the full Gilead Sciences profile (consensus, analyst reliability, price target, performance).